Paul Hastings Advises Organovo Holdings in Sale of FXR Program to Eli Lilly
Paul Hastings LLP advised Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease, in the sale of its FXR program, including lead program asset FXR314, to Eli Lilly and Company (NYSE:LLY).
Chair of the Palo Alto Corporate Department Jeff Hartlin and partner Samantha Eldredge led the Paul Hastings team, which also included partners Lucas Rachuba and Todd Schneider and associates Maggie Chou and Daniel Jun.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.